Rocket Pharmaceuticals, Inc. (RCKT)
After hours:
| Previous close | 23.67 |
| Open | 23.87 |
| Bid | 23.58 x 100 |
| Ask | 23.66 x 100 |
| Day's range | 23.31 - 24.24 |
| 52-week range | 14.89 - 32.53 |
| Volume | |
| Avg. volume | 717,617 |
| Market cap | 2.139B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.92 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.33 |
Insider MonkeyShould You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
ZacksEMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Business WireRocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
CRANBURY, N.J., April 02, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102, its lentiviral (LV) vector-based investigational gene therapy for Fanconi Anemia (FA), complementation group A, a rare genetic disorder caused by muta
